Research programme: anticancer antibodies - EvoGenix/Viventia Biotech
Alternative Names: Anticancer antibodies research programme - EvoGenix/Viventia BiotechLatest Information Update: 03 Dec 2007
At a glance
- Originator EvoGenix; Viventia Biotech
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Nov 2007 Discontinued - Preclinical for Cancer in Australia (unspecified route)
- 03 Nov 2007 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 14 Jun 2004 Preclinical trials in Cancer in Australia (unspecified route)